1. Home
  2. VTAK vs RNAZ Comparison

VTAK vs RNAZ Comparison

Compare VTAK & RNAZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Catheter Precision Inc.

VTAK

Catheter Precision Inc.

HOLD

Current Price

$0.15

Market Cap

1.8M

Sector

Health Care

ML Signal

HOLD

Logo TransCode Therapeutics Inc.

RNAZ

TransCode Therapeutics Inc.

N/A

Current Price

$1.79

Market Cap

2.0M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
VTAK
RNAZ
Founded
2002
2016
Country
United States
United States
Employees
N/A
N/A
Industry
Medical/Dental Instruments
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.8M
2.0M
IPO Year
2018
2021

Fundamental Metrics

Financial Performance
Metric
VTAK
RNAZ
Price
$0.15
$1.79
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
938.1K
45.0K
Earning Date
08-11-2026
04-15-2026
Dividend Yield
N/A
N/A
EPS Growth
89.53
N/A
EPS
N/A
N/A
Revenue
$442,000.00
N/A
Revenue This Year
$1,170.33
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
3057.14
N/A
52 Week Low
$0.15
$1.58
52 Week High
$3.20
$20.99

Technical Indicators

Market Signals
Indicator
VTAK
RNAZ
Relative Strength Index (RSI) 28.15 27.29
Support Level N/A N/A
Resistance Level $0.21 $9.37
Average True Range (ATR) 0.01 0.18
MACD 0.01 0.10
Stochastic Oscillator 10.03 15.75

Price Performance

Historical Comparison
VTAK
RNAZ

About VTAK Catheter Precision Inc.

Catheter Precision Inc is engaged in the design, manufacture, and sale of medical technologies focused in the field of cardiac electrophysiology, or EP. The company's two primary products include the VIVO System and LockeT. The VIVO System, which is an acronym for View into Ventricular Onset System(VIVO or VIVO System), is a non-invasive imaging system that offers 3D cardiac mapping to help with localizing the sites of origin of idiopathic ventricular arrhythmias in patients with structurally normal hearts prior to EP procedures. Its newest product, LockeT, is a suture retention device indicated for wound healing by distributing suture tension over a larger area in the patient in conjunction with a figure of eight suture closure.

About RNAZ TransCode Therapeutics Inc.

TransCode Therapeutics Inc is a clinical-stage biotechnology company engaged in the development of RNA-based therapeutics and immuno-oncology treatments for cancer. The company's lead candidate, TTX-MC138, targets microRNA-10b and has completed a Phase 1a clinical trial, while it is also advancing additional product candidates, including a cancer vaccine and an oncolytic immunotherapy platform.

Share on Social Networks: